KIT and melanoma: In addition to its single agent activity, cell-culture experiments have demonstrated an antiproliferative synergy between dasatinib and chemotherapeutic agents including cisplatin (Homsi et al, 2009) and temozolomide (Eustace et al, 2008) in c-Kit wild-type melanoma.